SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001737287-20-000029
Filing Date
2020-05-29
Accepted
2020-05-29 08:08:05
Documents
14
Period of Report
2020-05-29
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K allo-20200529.htm   iXBRL 8-K 91727
  Complete submission text file 0001737287-20-000029.txt   239791

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20200529.xsd EX-101.SCH 2649
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20200529_cal.xml EX-101.CAL 795
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20200529_def.xml EX-101.DEF 1759
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20200529_lab.xml EX-101.LAB 24270
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20200529_pre.xml EX-101.PRE 12731
12 EXTRACTED XBRL INSTANCE DOCUMENT allo-20200529_htm.xml XML 10789
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 20924079
SIC: 2836 Biological Products, (No Diagnostic Substances)